Co-delivery of paclitaxel and etoposide prodrug by human serum albumin and PLGA nanoparticles: synergistic cytotoxicity in brain tumour cells

References

• Bhattacharjee, S., 2022. Craft of co-encapsulation in nanomedicine: a struggle to achieve synergy through reciprocity. ACS pharmacology and translational science, 5 (5), 278–298.
   PubMedGoogle Scholar
• Cahan, M.A., et al., 1994. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer chemotherapy and pharmacology, 33 (5), 441–444.
   PubMed Web of Science ®Google Scholar
• Caliskan, Y., et al., 2019. A new therapeutic combination for osteosarcoma: Gemcitabine and Clofazimine co-loaded liposomal formulation. International journal of pharmaceutics, 557, 97–104.
   PubMed Web of Science ®Google Scholar
• Campos, F.C., et al., 2014. Systemic toxicity induced by paclitaxel in vivo is associated with the solvent cremophor EL through oxidative stress-driven mechanisms. Food and chemical toxicology, 68, 78–86.
   PubMed Web of Science ®Google Scholar
• Chatterjee, M., et al., 2017. Caveolae-mediated endocytosis is critical for albumin cellular uptake and response to albumin-bound chemotherapy. Cancer research, 77 (21), 5925–5937.
   PubMed Web of Science ®Google Scholar
• Coors, E.A., et al., 2005. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Annals of allergy, asthma and immunology, 95 (6), 593–599.
   PubMed Web of Science ®Google Scholar
• Das, V., and Miller, J.H., 2012. Non-taxoid site microtubule-stabilizing drugs work independently of tau overexpression in mouse N2a neuroblastoma cells. Brain research, 1489, 121–132.
   PubMed Web of Science ®Google Scholar
• Dash, A.K., 2010. The dark side of paclitaxel. Oncology reviews, 4 (2), 71–72.
   Google Scholar
• Desai, N. P., et al., 2004. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof. United States Patent.
   Google Scholar
• Duan, R., et al., 2017. Polymer-lipid hybrid nanoparticles-based paclitaxel and etoposide combinations for the synergistic anticancer efficacy in osteosarcoma. Colloids and surfaces B, 159, 880–887.
   PubMed Web of Science ®Google Scholar
• Eser, H., and Tihminlioglu, F., 2006. Determination of thermodynamic and transport properties of solvents and non solvents in poly(L-lactide-co-glycolide). Journal of applied polymer science, 102 (3), 2426–2432.
   Web of Science ®Google Scholar
• Fellner, S., et al., 2002. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. Journal of clinical investigation, 110 (9), 1309–1318.
   PubMed Web of Science ®Google Scholar
• Filon, O., et al., 2017. A phase I study of safety and pharmacokinetics of NanoBB-1-Dox in patients with advanced solid tumors. Journal of clinical oncology, 35 (15 Suppl), e13537–e13537.
   Web of Science ®Google Scholar
• Hahn, S.M., et al., 1993. Taxol in combination with doxorubicin or etoposide possible antagonism in vitro. Cancer, 72 (9), 2705–2711.
   PubMed Web of Science ®Google Scholar
• Huang, T., et al., 2012. Synergistic increase in the sensitivity of osteosarcoma cells to thermochemotherapy with combination of paclitaxel and etoposide. Molecular medicine reports, 6 (5), 1013–1017.
   PubMed Web of Science ®Google Scholar
• Kang, L., et al., 2015. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta pharmaceutica sinica B, 5 (3), 169–175.
   PubMed Web of Science ®Google Scholar
• Kano, Y., et al., 1999. Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro. Cancer chemotherapy and pharmacology, 44 (5), 381–388.
   PubMed Web of Science ®Google Scholar
• Kiya, K., et al., 1992. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer chemotherapy and pharmacology, 29 (5), 339–342.
   PubMed Web of Science ®Google Scholar
• Kreuter, J., 2014. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Advanced drug delivery reviews, 71, 2–14.
   PubMed Web of Science ®Google Scholar
• Kuhn, M., and von Wartburg, A., 1969. On a new glycoside synthesis process. II. Glycosides of 4’-demethylepipodophyllotoxins. Helvetica chimica acta, 52 (4), 948–957.
   PubMed Web of Science ®Google Scholar
• Kumskova, N., et al., 2020. How subtle differences in polymer molecular weight affect doxorubicin-loaded PLGA nanoparticles degradation and drug release. Journal of microencapsulation, 37 (3), 283–295.
   PubMed Web of Science ®Google Scholar
• Lagas, J.S., et al., 2010. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clinical cancer research, 16 (1), 130–140.
   PubMed Web of Science ®Google Scholar
• Leonard, A., and Wolff, J.E., 2013. Etoposide improves survival in high-grade glioma: a meta-analysis. Anticancer research, 33 (8), 3307–3315.
   PubMed Web of Science ®Google Scholar
• Li, Y., et al., 2020. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy. Drug delivery, 27 (1), 1044–1053.
   PubMed Web of Science ®Google Scholar
• Lidar, Z., et al., 2004. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. Journal of neurosurgery, 100 (3), 472–479.
   PubMed Web of Science ®Google Scholar
• Liederer, B.M., and Borchardt, R.T., 2006. Enzymes involved in the bioconversion of ester-based prodrugs. Journal of pharmaceutical sciences, 95 (6), 1177–1195.
   PubMed Web of Science ®Google Scholar
• Lin, T., et al., 2016. Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS nano. 10 (11), 9999–10012.
   PubMed Web of Science ®Google Scholar
• Lipinski, C.A., et al., 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews, 46 (1-3), 3–26.
   PubMed Web of Science ®Google Scholar
• van de Loosdrecht, A.A., et al., 1994. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. Journal of immunological methods, 174 (1–2), 311–320.
   PubMed Web of Science ®Google Scholar
• Mahira, S., et al., 2019. Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate cancer. Biomedicine and pharmacotherapy, 110, 803–817.
   PubMed Web of Science ®Google Scholar
• Maier, R., et al., 2021. Human versus bovine serum albumin: a subtle difference in hydrophobicity leads to large differences in bulk and interface behavior. Crystal growth and design, 21 (9), 5451–5459.
   Web of Science ®Google Scholar
• Maksimenko, O., et al., 2019. Doxorubicin-loaded PLGA nanoparticles for the chemotherapy of glioblastoma: towards the pharmaceutical development. International journal of pharmaceutics, 572, 118733.
   PubMed Web of Science ®Google Scholar
• Maleki, H., et al., 2021a. Effect of paclitaxel/etoposide co-loaded polymeric nanoparticles on tumor size and survival rate in a rat model of glioblastoma. International journal of pharmaceutics, 604, 120722.
   PubMed Web of Science ®Google Scholar
• Maleki, H., et al., 2021b. Preparation of paclitaxel and etoposide co-loaded mPEG-PLGA nanoparticles: an investigation with artificial neural network. Journal of pharmaceutical innovation, 16 (1), 11–25.
   Web of Science ®Google Scholar
• Mendes, L.P., Pan, J., and Torchilin, V.P., 2017. Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules, 22 (9), 1401–1421.
   PubMed Web of Science ®Google Scholar
• Montecucco, A., Zanetta, F., and Biamonti, G., 2015. Molecular mechanisms of etoposide. EXCLI journal, 14, 95–108.
   PubMed Web of Science ®Google Scholar
• Moya, E., et al., 2022. Interaction of surfactant coated PLGA nanoparticles with in vitro human brain-like endothelial cells. International journal of pharmaceutics, 621, 121780.
   PubMed Web of Science ®Google Scholar
• Neil, I., and Desai, I., 2007. Nab technology: a drug delivery platform utilizing endothelial gp60 receptor-based transport and tumor-derived SPARC for targeting. Drug delivery report, 16, 37–41.
   Google Scholar
• Ohnuma, T., et al., 1992. Preparation and antitumor activity of 2’’-O-, 3’’-O- and 2’’,3’’-di-O-substituted derivatives of etoposide. Chemical & pharmaceutical bulletin, 40 (7), 1783–1788.
   PubMed Web of Science ®Google Scholar
• Palmer, A.C. and Sorger, P.K., 2017. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell, 171 (7), 1678–1691.e13. e13.
   PubMed Web of Science ®Google Scholar
• Pan, J., et al., 2019. Polymeric co-delivery systems in cancer treatment: an overview on component drugs’ dosage ratio effect. Molecules, 24 (6), 1035–1066.
   PubMed Web of Science ®Google Scholar
• Pereverzeva, E., et al., 2019. Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastoma. International journal of pharmaceutics, 554, 161–178.
   PubMed Web of Science ®Google Scholar
• Perez, C., Daniel, K.B., and Cohen, S.M., 2013. Evaluating prodrug strategies for esterase-triggered release of alcohols. ChemMedChem. 8 (10), 1662–1667.
   PubMed Web of Science ®Google Scholar
• Perez, E.A., Buckwalter, C.A., and Reid, J.P., 1996. Combinations of paclitaxel and etoposide in the treatment of lung cancer. Seminars in oncology, 6 (15), 21–25.
   Google Scholar
• Ramón Y Cajal, S., et al., 2020. Clinical implications of intratumor heterogeneity: challenges and opportunities. Journal of molecular medicine, 98 (2), 161–177.
   PubMed Web of Science ®Google Scholar
• Reck, M., et al., 2003. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. Journal of the national cancer institute, 95 (15), 1118–1127.
   PubMedGoogle Scholar
• Sarisozen, C., et al., 2017. Polymers in the co-delivery of siRNA and anticancer drugs to treat multidrug-resistant tumors. Journal of pharmaceutical investigation, 47 (1), 37–49.
   Google Scholar
• Siestma, H., et al., 2000. 1-Phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for Taxol and vincristine. Clinical cancer research, 6 (3), 942–948.
   PubMed Web of Science ®Google Scholar
• Sriraman, S.K., et al., 2016. Enhanced cytotoxicity of folic acid-targeted liposomes co-loaded with C6 ceramide and doxorubicin: in vitro evaluation on HeLa, A2780-ADR, and H69-AR cells. Molecular pharmaceutics, 13 (2), 428–437.
   PubMed Web of Science ®Google Scholar
• Tan, A.C., et al., 2020. Management of glioblastoma: state of the art and future directions. CA: a cancer journal for clinicians, 70 (4), 299–312.
   PubMed Web of Science ®Google Scholar
• Veber, D.F., et al., 2002. Molecular properties that influence the oral bioavailability of drug candidates. Journal of medicinal chemistry, 45 (12), 2615–2623.
   PubMed Web of Science ®Google Scholar
• Wang, B., et al., 2015a. Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma. Journal of nanobiotechnology, 13 (1), 22–32.
   PubMed Web of Science ®Google Scholar
• Wang, Z., et al., 2015b. Development of etoposide-loaded bovine serum albumin nanosuspensions for parenteral delivery. Drug delivery, 22 (1), 79–85.
   PubMed Web of Science ®Google Scholar
• Weaver, B.A., 2014. How taxol/paclitaxel kills cancer cells. Molecular biology of the cell, 25 (18), 2677–2681.
   PubMed Web of Science ®Google Scholar
• Weiszhár, Z., et al., 2012. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. European journal of pharmaceutical sciences, 45 (4), 492–498.
   PubMed Web of Science ®Google Scholar
• Wu, D., et al., 2020. Design principles of drug combinations for chemotherapy. Journal of controlled release, 323, 36–46.
   PubMed Web of Science ®Google Scholar
• Xu, Z., et al., 2015. Glutathione- and pH-responsive nonporous silica prodrug nanoparticles for controlled release and cancer therapy. Nanoscale, 7 (13), 5859–5868.
   PubMed Web of Science ®Google Scholar
• Yardley, D.A., 2013. Drug resistance and the role of combination chemotherapy in improving patient outcomes. International journal of breast cancer, 2013, 1–15.
   Google Scholar
• Yi, X., et al., 2015. Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers. Molecular pharmaceutics, 12 (11), 4085–4098.
   PubMed Web of Science ®Google Scholar
• Zensi, A., et al., 2009. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. Journal of controlled release, 137 (1), 78–86.
   PubMed Web of Science ®Google Scholar
• Zhang, D.Y., et al., 2020. Ultrasound-mediated delivery of paclitaxel for glioma: a comparative study of distribution, toxicity, and efficacy of albumin-bound versus cremophor formulations. Clinical cancer research, 26 (2), 477–486.
   PubMed Web of Science ®Google Scholar
• Zhang, L., et al., 2013. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors. Clinical cancer research, 19 (21), 5972–5983.
   PubMed Web of Science ®Google Scholar